Buy, Sell, Or Hold Alnylam Stock At $280?
ALNY Stock
Alnylam Pharmaceuticals (NASDAQ:ALNY), a biotech company specializing in RNA interference therapeutics for genetically defined diseases, has experienced remarkable growth with its stock price surging from below $150 in March 2024 to over $280 currently, representing nearly a 100% increase.
This impressive performance was largely driven by promising clinical trial results for its cardiovascular drug Amvuttra released in mid-2024. Today marks another significant milestone as the FDA has expanded Amvuttra’s approval to include a broader patient population with a genetic heart condition, building upon its existing approval for treating protein accumulation in nerves. [1]
The expanded approval carries…
